A. Albiglutide B. Dulaglutide C. Exenatide D. Liraglutide

A. Basal insulin B. DPP-4 inhibitors C. Prandial insulin D. SGLT2 inhibitors

A. Increasing glucagon secretion B. Increasing insulin sensitivity C. Increasing glucose-dependent insulin secretion D. Decreasing hepatic glucose production

A. Albiglutide B. Dulaglutide C. Exenatide once weekly D. Liraglutide

A. Ask close-ended questions during individualized counseling to address potential adherence barriers. B. Provide personalized education and counseling to address individual barriers that may hinder adherence. C. Recommend a longer and wider needle for patients fearful of pain associated with injections. D. Threaten patients that non-adherence to oral antidiabetic medications will require the use of insulin.